Searched for
BIOCON ACQUISITION OF VIATRIS
The alchemist of Bengaluru: Kiran Mazumdar-Shaw began from a garageKiran Mazumdar-Shaw has named her niece Claire Mazumdar as successor, setting up a gradual leadership transition at Biocon. A pioneer who b...- S&P Global upgrades Biocon Biologics credit rating To 'BB+'Biocon Biologics has received a credit rating upgrade from S&P Global Ratings. The company's long-term issuer credit rating is now 'BB+' wi...
- Biocon betting big on new product launches for growthBiocon aims to grow through new product launches in generics and biosimilars, bolstered by the Viatris acquisition. This strategy integrate...
- Biocon Biologics is planning to raise $950 million through overseas bondsBiocon Biologics plans to raise $950 million through overseas bond sales to refinance a significant portion of its $1.2-billion debt from a...
- Biocon Biologics to raise debt of Rs 4,500 crore for Viatris PayoutBiocon Biologics plans to raise ₹4,500 crore with HSBC and MUFG's aid for a $175 million Aflibercept option. Previous funding by Kotak and ...
- Kotak Fund to part finance matrix lab founder's Viatris buyThe fund plans to provide a $150 million mezzanine debt facility at 18-20% and arrange another $300 million from other lenders to finance t...
- Biocon Q3 Results: PAT at Rs 660 crore vs Rs 42-crore loss a year agoThe company said the revenue growth was supported by income from the divesture of two non-core business assets of Biocon Biologics' branded...
- Biocon Biologics completes integration of Viatris' Europe biosimilar businessBiocon Biologics on Thursday said it has completed the integration of the acquired biosimilar business from Viatris Inc in 31 European coun...
- Biocon Q2 Results: Profit zooms 168% YoY to Rs 126 crore; revenue jumps 49%EBITDA for the quarter increased by 68% YoY to Rs 900 crore, representing an EBITDA margin of 25% versus 22% in the same period last year. ...
- Biocon raises $129 million from Kotak to fund biosimilars dealIndia's Kotak Mahindra Group asset management arm said on Wednesday it will invest 10.70 billion rupees ($129 million) in Biocon Ltd to hel...
- Biocon Biologics has comprehensive plan to integrate Viatris business: Shreehas Tambe, Biocon Biologics"There are several other discussions that we have been having with private equity investors who are interested in making an investment in B...
- Biocon completes $3.34 billion acquisition of Viatris's biosimilar businessTo fund the upfront payment, Biocon Biologics has secured $1.2 billion of Sustainability Linked Loan (SLL). The balance has been funded thr...
- Biocon Biologics allots equity shares worth Rs 2,205.63 crore to its parentAt the time of announcing the deal to acquire Viatris, BBL had said it would be through a cash payment of USD 2 billion, which would be fun...
- Biocon Biologics secures regulatory approvals for acquisition of Viatris' biosimilar businessThe transaction with US-based Viatris required regulatory approvals from the Reserve Bank of India, Competition Commission of India and the...
- Biocon Biologics expects big gains from integration of Viatris business, SII dealBiocon Biologics in March entered into a definitive agreement to acquire Viatris' biosimilars assets for $3.34 billion. It will pay Viatris...
- Biocon Biologics may close $3.34 billion Viatris deal in Q1Out of $2 billion, $800 million will come through equity infusion from existing investors including parent Biocon and others such as Serum ...
- Biocon Biologics to raise $1.2 billion overseas loan for Viatris dealBiocon Biologics, a unit of Biocon, is raising $1.2 billion via an offshore loan with the pharmaceutical company likely appointing HSBC, MU...
- Viatris deal pinches Biocon, but may prove a good betThe $3.3-billion acquisition - that includes $2.3 billion cash and a 12.9% equity stake in BBL - stands at over half of the market cap of B...
- Biocon arm to buy US company Biosimilar biz for $3.34 billionBiocon Biologics (BBL) will get the global biosimilar business of Viatris in developed and emerging markets, with an estimated revenue of $...
- Biocon Biologics acquires Viatris' biosimilar business for $3.34 billionBBL said the cash payment of $2 billion to be funded by $800 million raised through equity infusion in BBL and the remainder to be funded b...
Load More
